Biden's Pharma Policies will Likely Lead to Drug Shortages

INTERVIEW ON THE PRICE OF BUSINESS SHOW, MEDIA PARTNER OF THIS SITE.

Recently Kevin Price, Host of the nationally syndicated Price of Business Show, interviewed Casey Mulligan, Former Chief Economist of the White House Council of Economic Advisers (2018-19).

Price and Mulligan take a closer look at President Biden’s prescription drug policies, including:

* The likely shortage of many medications

* The undermining of innovation in drug creation

* The type of innovations the US should pursue to help reduce drug costs and keep them abundantly available.

According to the NY Times, “Mulligan is affiliated with a number of professional organizations, including the National Bureau of Economic Research, the George J. Stigler Center for the Study of the Economy and the State, and the Population Research Center. He is also the recipient of numerous awards and fellowships, including those from the National Science Foundation, the Alfred P. Sloan Foundation, the Smith- Richardson Foundation, and the John M. Olin Foundation.

“Professor Mulligan received his Ph.D. in economics from the University of Chicago in 1993. He has also served as a visiting professor teaching public economics at Harvard University, Clemson University, and Irving B. Harris Graduate School of Public Policy Studies at the University of Chicago.”

For more great national news content see our national news section.

LISTEN TO THE INTERVIEW IN ITS ENTIRETY HERE

About Author

admin

The news team of The Daily Blaze guest writers, and our contributors, which includes award winning journalists, continuously update this site with the best in writing.

No articles on this site should be construed as the opinion of The Daily Blaze or PriceofBusiness.com. Do your homework, get expert advice before following the advice on this or any other site.

See author's posts